834 related articles for article (PubMed ID: 22338670)
21. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
[TBL] [Abstract][Full Text] [Related]
24. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
25. Trends in treated ventricular fibrillation out-of-hospital cardiac arrest: a 17-year population-based study.
Bunch TJ; White RD; Friedman PA; Kottke TE; Wu LA; Packer DL
Heart Rhythm; 2004 Sep; 1(3):255-9. PubMed ID: 15851165
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis.
Aizer A; Stern EH; Gomes JA; Teirstein AS; Eckart RE; Mehta D
Am J Cardiol; 2005 Jul; 96(2):276-82. PubMed ID: 16018857
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis.
Flamée L; Symons R; Degtiarova G; Dresselaers T; Gheysens O; Wuyts W; Van Cleemput J; Bogaert J
Eur Radiol; 2020 Jul; 30(7):3702-3710. PubMed ID: 32166494
[TBL] [Abstract][Full Text] [Related]
28. Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience.
Caputo ML; Regoli F; Conte G; Adjibodou B; Svab S; Del Bufalo A; Moccetti T; Curti M; Klersy C; Auricchio A
Int J Cardiol; 2017 Feb; 228():31-36. PubMed ID: 27863358
[TBL] [Abstract][Full Text] [Related]
29. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
30. [Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients].
Piekarz J; Rydlewska A; Majewski J; Lelakowski J
Pol Merkur Lekarski; 2012 Jun; 32(192):368-73. PubMed ID: 22891561
[TBL] [Abstract][Full Text] [Related]
31. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
Saeed M; Neason CG; Razavi M; Chandiramani S; Alonso J; Natarajan S; Ip JH; Peress DF; Ramadas S; Massumi A
J Cardiovasc Electrophysiol; 2010 Dec; 21(12):1349-54. PubMed ID: 20561107
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
[TBL] [Abstract][Full Text] [Related]
33. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.
Coleman CI; Kluger J; Bhavnani S; Clyne C; Yarlagadda R; Guertin D; White CM
Heart Rhythm; 2008 Apr; 5(4):507-10. PubMed ID: 18362016
[TBL] [Abstract][Full Text] [Related]
34. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
36. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
Grimm W; Plachta E; Maisch B
Pacing Clin Electrophysiol; 2006 Jul; 29(7):759-64. PubMed ID: 16884513
[TBL] [Abstract][Full Text] [Related]
37. Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
Voskoboinik A; Bloom J; Taylor A; Mariani J
Pacing Clin Electrophysiol; 2016 Sep; 39(9):992-8. PubMed ID: 27343008
[TBL] [Abstract][Full Text] [Related]
38. Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.
House CM; Nguyen D; Thomas AJ; Nelson WB; Zhu DW
J Card Fail; 2016 Feb; 22(2):125-32. PubMed ID: 26522819
[TBL] [Abstract][Full Text] [Related]
39. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients.
Hayashi Y; Takagi M; Kakihara J; Sakamoto S; Doi A; Sugioka K; Hanatani A; Yoshiyama M
Heart Vessels; 2017 Feb; 32(2):175-185. PubMed ID: 27259484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
